argenx SE (NASDAQ:ARGX) Short Interest Update

argenx SE (NASDAQ:ARGX – Get Rating) saw a sharp decline in short-term interest in July. As of July 31, there was short interest totaling 947,300 shares, down 51.2% from the July 15 total of 1,940,000 shares. Based on an average trading volume of 323,100 shares, the day-to-cover ratio is currently 2.9 days.

Wall Street analysts predict growth

Several research companies have recently published reports on ARGX. JPMorgan Chase & Co. raised its price target on argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the stock an “overweight” rating in a research note Thursday, July 14. Robert W. Baird reiterated a “downgraded” rating on Argenx stock in a Friday, July 29 research note. Stifel Nicolaus raised his price target on argenx from $460.00 to $471.00 in a Thursday, July 28 research note. SVB Leerink raised its price target on argenx from $404.00 to $428.00 and gave the stock an “outperforming” rating in a Friday, July 29 research note. Finally, Deutsche Bank Aktiengesellschaft upgraded argenx from a “hold” rating to a “buy” rating in a Friday, May 13 research report. One investment analyst gave the stock a hold rating, fifteen gave the stock a buy rating and one gave the stock a high buy rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $395.00.

Hedge funds weigh on argenx

Several large investors have recently increased or reduced their holdings in ARGX. KB Financial Partners LLC increased its stake in argenx by 112.5% ​​in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company valued at $27,000 after acquiring 45 additional shares in the last quarter. Glassman Wealth Services increased its stake in argenx by 69.4% in the second quarter. Glassman Wealth Services now owns 83 shares of the company valued at $31,000 after acquiring 34 additional shares in the last quarter. CWM LLC increased its stake in argenx by 107.3% in the 2nd quarter. CWM LLC now owns 114 shares of the company valued at $43,000 after acquiring 59 additional shares in the last quarter. Captrust Financial Advisors increased its position in argenx by 116.7% in the first quarter. Captrust Financial Advisors now owns 143 shares of the company valued at $45,000 after buying 77 additional shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in argenx by 126.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 174 shares of the company valued at $55,000 after buying 97 additional shares in the last quarter. Institutional investors and hedge funds own 58.76% of the company’s shares.

argentx Stock up 0.7%

A d Invest daily

Could Apple’s next “star product” replace the iPhone?

Apple’s next “flagship” could be its most profitable yet and could dominate a fast-growing new industry that Morgan Stanley projects will be worth $10 trillion! The new “profit machine” could offer early investors a salary of $190,717. How can you lock your shot at 20 times your money? See here.

Argenx stock traded at $2.77 during Friday trading hours, hitting $376.91. The stock had a trading volume of 352,109 shares, compared to an average volume of 228,022. The company has a 50-day moving average of $359.23 and a two-hundred-day moving average of $320.32. The company has a market capitalization of $20.75 billion, a PE ratio of -21.75 and a beta of 0.84. silverx has a fifty-two week low of $249.50 and a fifty-two week high of $387.89.

Argenx Company Profile

(Get an assessment)

argenx SE, a biotechnology company, is focused on the development of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic inflammatory demyelinating polyneuropathy in phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in phase II/III clinical trials; and ENHANZE SC in the preclinical study.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider argentx, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and argenx didn’t make the list.

While Argenx currently has a “Buy” rating among analysts, the top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.